Altimmune, Inc.
ALT
$5.61
-$0.36-6.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -95.31% | -81.36% | 604.94% | 618.99% | 726.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.31% | -81.36% | 604.94% | 618.99% | 726.47% |
| Cost of Revenue | 24.97% | 16.58% | 11.43% | -3.64% | -9.01% |
| Gross Profit | -25.75% | -16.98% | -10.72% | 4.31% | 9.69% |
| SG&A Expenses | 15.60% | 14.75% | 12.31% | 9.75% | 5.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.94% | 16.20% | 11.61% | -1.07% | -6.17% |
| Operating Income | -23.54% | -16.52% | -11.04% | 1.62% | 6.71% |
| Income Before Tax | -7.48% | -31.93% | -24.34% | -8.43% | -4.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.48% | -31.93% | -24.64% | -8.68% | -4.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.48% | -31.93% | -24.64% | -8.68% | -4.41% |
| EBIT | -23.54% | -16.52% | -11.04% | 1.62% | 6.71% |
| EBITDA | -23.98% | -17.29% | -11.50% | 1.42% | 6.58% |
| EPS Basic | 18.58% | -1.24% | 0.53% | 8.41% | 7.39% |
| Normalized Basic EPS | 6.50% | 12.60% | 13.80% | 20.84% | 21.33% |
| EPS Diluted | 18.58% | -0.69% | 1.21% | 9.00% | 7.97% |
| Normalized Diluted EPS | 6.50% | 12.60% | 13.80% | 20.84% | 21.33% |
| Average Basic Shares Outstanding | 33.43% | 32.66% | 26.82% | 18.60% | 11.59% |
| Average Diluted Shares Outstanding | 33.43% | 32.66% | 26.82% | 18.60% | 11.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
